MEDI4212

MEDI4212 is a human monoclonal IgG antibody developed as a high-affinity anti-IgE therapy for allergic conditions. It binds specifically to immunoglobulin E (IgE) and blocks its interaction with both the high-affinity IgE receptor (FcεRI) and CD23, thereby inhibiting the downstream allergic inflammatory cascade. Compared to omalizumab, another anti-IgE antibody, MEDI4212 demonstrated more rapid and potent suppression of free serum IgE but with a shorter duration of effect. The drug was investigated primarily for allergic asthma, atopic dermatitis, and allergic rhinitis but development was discontinued after phase 1 trials due to limited clinical advantages in dosing schedule or efficacy over existing therapies[2][3][8].